The tesamorelin and BPC-157 stack pairs a growth hormone releasing peptide with a repair peptide. Learn how each works, dosing considerations, and safety risks.
The tesamorelin and BPC-157 stack combines an FDA-approved growth hormone–releasing peptide with a research peptide that has no approved human use. Tesamorelin (brand name Egrifta) is approved for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, while BPC-157 is not approved for human use in the United States. The two are discussed together because they work through completely different pathways, but no published human trial has tested them as a combination.
What Tesamorelin Does
Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It binds to GHRH receptors in the pituitary gland and stimulates the body's own pulsatile growth hormone release, which in turn raises IGF-1.
- Approved use: reduction of excess visceral abdominal fat in HIV-positive adults with lipodystrophy.
- Form: daily subcutaneous injection (Egrifta WR is a once-weekly version).
- Status: prescription-only in the US.
- Studied effects: lower visceral fat, shifts in IGF-1, and modest changes in body composition.
What BPC-157 Does
BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment of human gastric juice protein. Almost all of the evidence comes from rodent studies that looked at tendon, ligament, muscle, gut-lining, and nerve healing.
- Approved use: none in the US; it is sold as a research chemical.
- Form: subcutaneous injection or oral capsules on the gray market.
- Human data: very limited, with no large randomized controlled trials.
Side-by-Side Comparison
| Feature | Tesamorelin | BPC-157 |
|---|---|---|
| Peptide class | GHRH analog | Synthetic gastric peptide fragment |
| Primary target | Pituitary GH release and IGF-1 | Tissue repair pathways (animal models) |
| FDA status | Approved as Egrifta for HIV lipodystrophy | Not approved for human use |
| Typical route | Subcutaneous injection | Subcutaneous injection or oral |
| Human evidence | Multiple clinical trials | Minimal |
| Main goal in a stack | Body composition, GH/IGF-1 support | Recovery, joint and gut comfort |
Why People Stack Tesamorelin and BPC-157
The logic behind the combination is straightforward: one peptide targets hormone signaling, and the other is studied for local tissue repair, so users assume the effects add up without overlapping.
- Different mechanisms: the two compounds share no receptor pathway.
- Different timing: tesamorelin is usually taken at night on an empty stomach to mimic natural GH pulses, while BPC-157 is discussed as once or twice daily at any hour.
- Different goals: fat loss and body composition on one side, recovery from training or nagging injuries on the other.
- Cost gap: tesamorelin is expensive, and BPC-157 is comparatively cheap.
Real-world reports about the stack are anecdotal, and anecdotes are not evidence. People who spend time in recovery forums also read about the bpc-157 and tb-500 wolverine stack, which pairs two repair peptides instead of adding a GH secretagogue.
Dosing Talk You Will See Online — and Why It Is Shaky
No published protocol defines a correct tesamorelin and BPC-157 stack, because the combination has never been studied in humans. What circulates online is a patchwork of individual reports and secondhand claims.
- Tesamorelin: the FDA label dose for approved use is 2 mg subcutaneously once daily, or 1.4 mg once weekly for the WR formulation. That is the only dose with regulatory backing.
- BPC-157: commonly discussed ranges run from roughly 250 mcg to 500 mcg per day, injected or oral, with no human trial to support them.
- Cycle length: forums often suggest 4 to 12 weeks, again without evidence.
Anyone considering injectable peptides should have a clinician review their health history first, because IGF-1 levels, blood glucose, and existing conditions all change the risk picture.
Safety and Side Effects
Tesamorelin's label lists injection-site reactions, joint pain, swelling, and elevated IGF-1 among the known effects. It is contraindicated during pregnancy and in people with active cancer or disrupted pituitary anatomy.
BPC-157's human safety profile is essentially unknown. Research-grade vials may also contain impurities, the wrong peptide, or the wrong concentration, which makes any self-reported reaction hard to interpret.
Combining the two adds another unknown: no study has tracked how a GHRH analog interacts with BPC-157 over weeks or months. Anyone using these compounds should talk with a licensed healthcare professional and get baseline bloodwork.
Legal Status and Sourcing
Tesamorelin requires a prescription in the United States, and buying it without one is illegal. BPC-157 sits in a gray zone because it is not approved for human use, so legitimate suppliers sell it labeled "for research use only."
People searching for where to buy bpc-157 and tb-500 run into the same problem: certificates of analysis are easy to fake, and the FDA has issued warnings about mislabeled peptides sold online. Testing is the only way to know what is actually in a vial, and most buyers never test.
Alternatives Discussed in the Same Circles
If the goal is GH support, the tesamorelin and cjc-1295 stack is a frequent comparison point, since CJC-1295 is a longer-acting GHRH analog that is often paired with ipamorelin. Some people weigh bpc 157 and cjc 1295 when they want repair support plus a GH signal in one routine.
For recovery-focused users, the bpc-157 and sermorelin stack mixes a repair peptide with a shorter-acting GH secretagogue, though sermorelin's human data is also limited. A common side question in these threads is, "What is the difference between KPV and BPC-157?" — KPV is a much shorter tripeptide studied mainly for inflammation, while BPC-157 is studied mainly for structural repair.
The Bottom Line
Tesamorelin has real clinical data behind it for one specific condition, and BPC-157 does not have approved human use anywhere. No trial has tested them together, so the stack's risks and benefits are unknown.
Peptides are not a substitute for medical care, and any decision to use them should go through a physician who can monitor labs and side effects. For most people, the evidence does not support stacking two injectable peptides without supervision.
Frequently Asked Questions
Can you stack tesamorelin and BPC-157?
You can physically combine them, but no published human clinical trial has tested the pair together. Tesamorelin is FDA-approved only for HIV-associated visceral fat, and BPC-157 is not approved for human use in the United States. Anyone considering the combination should discuss it with a licensed healthcare professional first.
Is tesamorelin FDA-approved for weight loss?
Tesamorelin is FDA-approved as Egrifta for reducing excess visceral abdominal fat in adults with HIV and lipodystrophy. It is not approved for general weight loss, anti-aging, or bodybuilding use. Using it outside that approved indication means using a prescription drug without regulatory guidance on dosing or monitoring.
What are the side effects of BPC-157?
Human safety data on BPC-157 is very limited, so a full side effect profile is not established. Animal studies report few serious issues, but research-grade products can be mislabeled or contaminated. Talk to a doctor before using any research peptide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.